

ORAL PRESENTATION

Open Access

Durable complete response in a patient with metastatic melanoma following adoptive transfer of autologous T cells recognizing 10 mutated tumor antigens

Todd D Prickett^{1*}, Jessica S Crystal², Jared J Gartner¹, Yao Xin¹, Pasetto Anna³, Alena Gros¹, Yong-Chen Lu³, Yong Li¹, Mona El-Gamil¹, Steven A Rosenberg³, Paul Robbins¹

From 30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015)

National Harbor, MD, USA. 4-8 November 2015

Durable complete response rates of 20% have been observed in clinical trials of patients with metastatic melanoma employing adoptive cell transfer (ACT) of patient derived tumor infiltrating lymphocytes (TIL). Here we provide a detailed analysis of the response of TIL administered to a patient with metastatic melanoma who exhibited a complete response ongoing greater than 3 years. Using whole exome and RNA sequencing and bioinformatic analysis of the patient's matched tumor and normal gDNA we identified over 4,000 non-synonymous somatic mutation variants. We screened 745 somatically mutated genes using tandem minigene constructs expressing transcripts expressed in autologous tumor cells whose expression levels were greater than 0.1% of the levels of β -actin. These tandem minigenes were then transfected into autologous B cells and then analyzed for their ability to stimulate the administered T cells. Our results indicated that the autologous TIL distinctly recognized 10 somatically mutated gene products, each of which was recognized in the context of three different HLA class I restriction elements expressed by the patient's tumor. Detailed T cell clonal analysis revealed that 9 of the top 20 most prevalent clones present in the infused TIL, comprised over $\frac{1}{4}$ of total infused cells and recognized mutated antigens. These results further supported our efforts to identify and enrich mutation-reactive T cells for the treatment of patients with metastatic cancer.

Authors' details

¹National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. ²National Cancer Institute, National Institutes of Health, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA. ³Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Published: 4 November 2015

doi:10.1186/2051-1426-3-S2-O4

Cite this article as: Prickett et al.: Durable complete response in a patient with metastatic melanoma following adoptive transfer of autologous T cells recognizing 10 mutated tumor antigens. *Journal for ImmunoTherapy of Cancer* 2015 **3**(Suppl 2):O4.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit



¹National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
Full list of author information is available at the end of the article